23andMe, the leading personal genetics company, has accumulated a wealth of genotypic and phenotypic information from participants committed to improving human health through advances in genomics. 23andMe’s research platform is currently the world’s largest consented, re-contactable database for genetic research. This data will lead to a better understanding of the biological mechanisms of disease, and accelerate the discovery of novel treatments through human genetics.
The Therapeutics Division was created in April 2015. The Therapeutics division is committed to discovering and developing novel therapies that can offer benefits for patients. This dedicated research and drug development group identifies novel targets using the 23andMe genetic database, generates lead compounds to these targets and performs preclinical research to support future clinical development. The team currently has research programs across several therapeutic areas, including oncology, skin, respiratory and cardiovascular disease.